The ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events) Study Group used a number of criteria to grade bleeding associated with heparin therapy.
Major bleeding:
(1) fatal bleeding
(2) symptomatic intracranial hemorrhage
(3) retroperitoneal hemorrhage
(4) intraocular hemorrhage leading to significant vision loss
(5) decrease in hemoglobin >= 3 g/dL
(6) need for red blood cell transfusion >= 2 units
Minor bleeding:
(1) all other clinically significant bleeding with one of the following:
(1a) interruption of anticoagulation therapy >= 24 hours
(1b) surgical intervention
(1c) transfusion of < 2 units of blood
To read more or access our algorithms and calculators, please log in or register.
